Pulse Biosciences Stock Investor Sentiment

PLSE Stock  USD 17.61  0.03  0.17%   
About 61% of all Pulse Biosciences' shareholders are looking to take a long position. The analysis of overall sentiment of trading Pulse Biosciences stock suggests that some investors are interested at this time. The current market sentiment, together with Pulse Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Pulse Biosciences stock news signals to limit their universe of possible portfolio assets.
  

Pulse Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pulse Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pulse Biosciences Maximum Pain Price Across April 17th 2025 Option Contracts

Pulse Biosciences' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Pulse Biosciences close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Pulse Biosciences' options.
over three months ago at businesswire.com         
Acquisition by Kevin Danahy of 460000 shares of Pulse Biosciences at 4.38 subject to Rule 16b-3
businesswire News
over three months ago at businesswire.com         
Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 202...
businesswire News
over six months ago at www.macroaxis.com         
Disposition of 543 shares by Barrett Burke Thomas of Pulse Biosciences at 11.0 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Pulse Biosciences Shares Gap Up to 16.38 - American Banking and Market News
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 543 shares by Burke Barrett of Pulse Biosciences at 11.0 subject to Rule 16b-3
Macroaxis News
over six months ago at simplywall.st         
Pulse Biosciences, Inc. insiders have had a fantastic week as stock increased 10, and they havent st...
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Pulse Biosciences Sets New 1-Year High at 20.44 - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Pulse Biosciences Shares Gap Down to 18.58 - American Banking and Market News
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Pulse Biosciences receives breakthrough device status for CellFX system
Yahoo News
over six months ago at finance.yahoo.com         
Pulse drops 510 plan for PFA device after FDA requests clinical data
Yahoo News
over six months ago at talkmarkets.com         
SP 500, Nasdaq Extend Record Highs Dow Up Triple Digits
news
over six months ago at finance.yahoo.com         
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX nsPFA Ca...
Yahoo News
over six months ago at seekingalpha.com         
Pulse stock rallies 22 percent on FDA breakthrough designation
seekingalpha News
over six months ago at massdevice.com         
Pulse Biosciences wins FDA breakthrough nod for AFib-treating pulsed field ablation tech
news
over six months ago at news.google.com         
Pulse Biosciences Trading Up 6.5 percent - Defense World
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Pulse Biosciences that are available to investors today. That information is available publicly through Pulse media outlets and privately through word of mouth or via Pulse internal channels. However, regardless of the origin, that massive amount of Pulse data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pulse Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pulse Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pulse Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pulse Biosciences alpha.

Pulse Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Zanganeh Mahkam of 200000 shares of Pulse Biosciences at 15.65 subject to Rule 16b-3
11/05/2024
2
Pulse Biosciences, Inc.s largest shareholder, Top Key Executive Robert Duggan sees holdings value fall by 4.8 percent following recent drop
11/15/2024
3
Pulse Biosciences announces CEO departure and interim leadership
12/06/2024
4
Acquisition by Robert Duggan of 6054 shares of Pulse Biosciences at 16.74 subject to Rule 16b-3
12/11/2024
5
Pulse Biosciences Trading Down 5.4 percent Should You Sell
12/12/2024
6
Acquisition by Robert Duggan of 55256 shares of Pulse Biosciences at 17.18 subject to Rule 16b-3
12/13/2024
7
Robert Duggan Spends US972k On Pulse Biosciences Stock
12/16/2024
8
Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery
12/17/2024
9
Disposition of 24656 shares by Robert Duggan of Pulse Biosciences at 11.0 subject to Rule 16b-3
12/18/2024
10
Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
12/19/2024
11
Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference
01/03/2025
12
Acquisition by Paul LaViolette of 450000 shares of Pulse Biosciences at 18.43 subject to Rule 16b-3
01/08/2025
13
Pulse Biosciences Inc Appoints New CEO and Announces Strategic Developments
01/10/2025
14
Pulse Biosciences Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium
01/13/2025

Complementary Tools for Pulse Stock analysis

When running Pulse Biosciences' price analysis, check to measure Pulse Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulse Biosciences is operating at the current time. Most of Pulse Biosciences' value examination focuses on studying past and present price action to predict the probability of Pulse Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulse Biosciences' price. Additionally, you may evaluate how the addition of Pulse Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Stocks Directory
Find actively traded stocks across global markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format